top of page

For Patients
For Healthcare Professionals
- Treating Stage 4 ROS1 (for HCPs)
- ROS1 Clinical Trials
Our Research
Blog
About Us
More

Use tab to navigate through the menu items.

ROS1ders Blog

Articles and Resources for ROS1+ Patients, Families, and Health Professionals.

All Posts
Advocacy
Biomarker Testing
Events
Patient-Driven Research
Cancer Progression
Research
Resources
Survivorship
Treatments and Trials
Fundraising
ROS1ders Stories

Search

Calling all ROS1ders! Please help Australians access Entrectinib

Calling all ROS1ders! Please help Australians access Entrectinib

Calling all ROS1ders! Please help Australians access Entrectinib

Jan 23, 20202 min read

ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

ROS1DERS: You can help Canadian ROS1+ NSCLC patients gain access to entrectinib!

Janet Freeman-Daily

Jan 5, 20201 min read

ROS1der acquires grant to research ROS1 progression

ROS1der acquires grant to research ROS1 progression

ROS1der acquires grant to research ROS1 progression

Joyce Hoelting and Geert Vandeweyer

Dec 29, 20193 min read

Confused about 1st and 2nd line drugs? Here’s a guide!

Confused about 1st and 2nd line drugs? Here’s a guide!

Confused about 1st and 2nd line drugs? Here’s a guide!

Dec 29, 20192 min read

Parenting after a ROS1+ Cancer Diagnosis

Parenting after a ROS1+ Cancer Diagnosis

Parenting after a ROS1+ Cancer Diagnosis

Dec 29, 20193 min read

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Thanks to ROS1ders’ Partner Turning Point Therapeutics

Janet Freeman-Daily

Nov 8, 20191 min read

Travel Tips

Travel Tips

Travel Tips

Aug 13, 20192 min read

Fundraising Update

Fundraising Update

Fundraising Update

Aug 5, 20191 min read

The Few…The Proud…The ROS1ders!

The Few…The Proud…The ROS1ders!

The Few…The Proud…The ROS1ders!

Jul 31, 20193 min read

The ROS1ders Interview Dr. Ross Camidge

The ROS1ders Interview Dr. Ross Camidge

The ROS1ders Interview Dr. Ross Camidge

Janet Freeman-Daily

May 15, 20191 min read

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

pCODR recommends pan-Canadian crizotinib first-line for ROS1+ NSCLC

Janet Freeman-Daily

May 4, 20191 min read

Donating ROS1 Tissue

Donating ROS1 Tissue

Donating ROS1 Tissue

Marisa Wittebort

Apr 30, 20192 min read

ROS1 by the Numbers

ROS1 by the Numbers

ROS1 by the Numbers

Apr 17, 20192 min read

ROS1 News From Europe

ROS1 News From Europe

ROS1 News From Europe

Bärbel Söhlke

Apr 15, 20192 min read

Addario to Merge with Lung Cancer Alliance

Addario to Merge with Lung Cancer Alliance

Addario to Merge with Lung Cancer Alliance

Mar 31, 20191 min read

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Entrectinib granted priority review for ROS1 NSCLC and NTRK solid tumors

Janet Freeman-Daily

Feb 18, 20191 min read

Advocating for ROS1

Advocating for ROS1

Advocating for ROS1

Janet Freeman-Daily

Jan 29, 20191 min read

Thinking about a “drug vacation” from crizotinib? Read this first!

Thinking about a “drug vacation” from crizotinib? Read this first!

Thinking about a “drug vacation” from crizotinib? Read this first!

Janet Freeman-Daily

Jan 16, 20193 min read

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Crizotinib approved for ROS1 in Australia

Janet Freeman-Daily

Dec 30, 20181 min read

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

NCCN Guidelines recommend lorlatinib for second-line ROS1+ NSCLC

Janet Freeman-Daily

Dec 13, 20181 min read

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

U.S. FDA Approves LORBRENA® (lorlatinib) for Previously-Treated ALK-Positive Metastatic NSCLC

Janet Freeman-Daily

Nov 4, 20181 min read

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Presentations on ROS1+ Cancer at IASLC #WCLC2018

Janet Freeman-Daily

Sep 10, 20186 min read

Detection of ROS1 rearrangement in lung cancer remains “complex”

Detection of ROS1 rearrangement in lung cancer remains “complex”

Detection of ROS1 rearrangement in lung cancer remains “complex”

Janet Freeman-Daily

Aug 31, 20181 min read

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Crizotinib may be effective again after chemo

Janet Freeman-Daily

Aug 26, 20181 min read

The ROS1ders, Inc.
1721 Eastern Avenue, Suite 19
Sacramento, CA 95864
+1 (916) 382-8544
info@theros1ders.org

A 501(c)(3) nonprofit corporation
EIN 83-4490547

Disclosures

This website is not intended to, and does not provide, medical advice, professional diagnosis, opinion, treatment, or services. Medical information provided on this site is for informational and educational purposes only. After reading content from this website, you are encouraged to review the information carefully with your physician.

Connect with Our Community

Join Private Facebook Group

Email Webmaster

bottom of page